Some studies question the validity ofA1C in the pediatric population, especiallyamong certain ethnicities, and suggestOGTT or FPG as more suitable diagnostictests (52). However, many of thesestudies do not recognize that diabetes diagnosticcriteria are based on long-termhealth outcomes, and validations are notcurrently available in the pediatric population(53). The ADA acknowledges thelimited data supporting A1C for diagnosingtype 2 diabetes in children andadolescents. Although A1C is not recommendedfor diagnosis of diabetes in childrenwith cystic fibrosis or symptomssuggestive of acute onset of type 1 diabetesand only A1C assays without interferenceare appropriate for children withhemoglobinopathies, the ADA continuesto recommend A1C for diagnosis of type 2diabetes in this cohort (54,55).